This Is MS Multiple Sclerosis Community: Knowledge & Support

In their opinion.... show me evidence not opinions.

Cases of death? as in plural?

Rox

Cases of death? as in plural?

Original press release (german): http://www.dgn.org/images/stories/dgn/p ... erapie.pdf

Translation:

Neurologists warn about dangerous treatment in multiple sclerosis

(September 17, 2010) The "Deutsche Gesellschaft für Neurologie" (German organisation for neurology) warns about futile and dangerous vascular surgeries in patients with multiple sclerosis. These surgeries are based on a scientifically untenable theory from the italian physician Paolo Zamboni about the genesis of the disease, leading neurologists criticise. Cases of death are already known. Background of the criticism is the so-called "venous congestion hypothesis" of multiple sclerosis, which is fiercely discussed also as "chronic cerebrospinal venous insufficiency" among experts and in patients forums and seemingly gets more and more followers. "In our opinion there's no sufficient evidence to this hypothesis and more than ever there's no cause for wanting to have the supposed vascular blockage removed in a so-called Liberation Treatment for several thousand euros." says MS-expert professor Hans-Peter Hartung from Düsseldorf, who will present new conclusions to this on the "Neurowoche 2010" (Neuroweek 2010) in Mannheim. With more than 6000 participants, the Neurowoche is the largest neuromedical convention in europe.

- - - - - - -

I have no words for that. Can someone react to it? CCSVI Alliance? Direct MS? I'm sure they won't care about what patients and relatives say, and there's no german organisation which would do that. But they all speak english very well...

Yes, they use plural.

THE WOODLANDS, Texas (August 5, 2010) – Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced it has reconstituted its Scientific Advisory Board with notable key opinion leaders in the MS field. Members of the Advisory Board include Dawn McGuire, M.D. (Chair); Doug Arnold, M.D.; Edward Fox, M.D., Ph.D.; Hans-Peter Hartung, M.D.; Clyde Markowitz, M.D.; Paul O’Connor, M.D.; Chris H. Polman, M.D. and Arthur Vandenbark, Ph.D..
"Opexa is developing Tovaxin, a novel immunotherapy for multiple sclerosis, and this board of advisors represents some of the best and most highly regarded neurologists and immunologists in the world. Each has developed substantial expertise relevant to the further development of Tovaxin including designing and participating in numerous MS clinical trials, understanding U.S. and EU regulatory requirements, new product development, and T-cell immunology and their guidance will be instrumental in our ongoing plans to advance Tovaxin," said Neil K. Warma, President and Chief Executive Officer. "We welcome these distinguished leaders to our team and greatly appreciate their interest and willingness to lend their considerable talents to our development efforts."

Hans-Peter Hartung, M.D. – Dr. Hartung holds the Chair of Neurology at Heinrich-Heine University, Düsseldorf and is chairman of the Department of Neurology. Professor Hartung is a member of a large number of international and nation societies, serving on executive boards (President ECTRIMS; European Neurological Society, International Society for Neuroimmunology, International Federation of Multiple Sclerosis Societies; World Health Organization Advisory Board on Multiple Sclerosis), as well as on the editorial board of a number of international journals. He has authored or co-authored more than 400 articles in peer reviewed journals, written more than 80 book chapters and edited 7 books on neurology, neuroimmunology, peripheral nerve disease and multiple sclerosis.

Current president (of ECTRIMS) Hans-Peter Hartung, MD, from Heinrich-Heine University in Düsseldorf, Germany, added, "It is a very exciting time in multiple sclerosis therapy research. This is the most active therapeutic field in all of neurology."

Dr. Hartung said that the new potent drugs are prompting neurologists to consult with their oncology and rheumatology colleagues on how to best manage immunosuppressive and cytotoxic agents.

Could it be possible that intelligent, educated people could be familiar with the "science" of CCSVI and still not buy it and at the same time aren't being guided by some kind of demonic ulterior motives?

Dr. Hartung might be a brilliant neurologist and a standup guy and all, but he invites the sort of response Cheer made by spewing out mud and misinformation.